Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 26, Issue 3, pp 175–182 | Cite as

Bleeding after antithrombotic therapy in patients with acute ischemic heart disease

Is it the drugs or how we use them?
  • Marc CohenEmail author
  • Karen P. Alexander
  • Sunil V. Rao
Article

Abstract

Definitions of bleeding must be considered when evaluating results of clinical trials. Assessments of bleeding impact based on clinical criteria may be more relevant to patient outcomes than those based on simple laboratory measures like an isolated change in hemoglobin, that do not appear to affect patient care. The risk of excessive bleeding in patients who receive antiplatelet and antithrombotic therapy is related to a combination of patient characteristics (older age, female sex, impaired renal function), and delivery factors (excessive dosing, stacking of anticoagulants). Investigators should justify components of bleeding endpoints as being clinically meaningful, sufficiently frequent in the study population, and affected by the intervention.

Keywords

Bleeding Acute coronary syndrome Hemorrhage Percutaneous coronary intervention 

Notes

Acknowledgments

Editorial assistance for this manuscript was provided by Adelphi, Inc., and funded by Schering-Plough Corporation.

Conflict of interest

Dr. Cohen has received grant/research support from Bayer, Sanofi Aventis. He is a consultant to Datascope and Schering-Plough. He is a member of the speakers’ bureau for Schering-Plough, Sanofi Aventis, Merck, and BMS.

Dr. Rao is a consultant to Sanofi Aventis and The Medicines Company. He is on the Speakers’ Bureaus of Sanofi Aventis, The Medicines Company, and Cordis Corporation. He receives research funding from The Medicines Company and Cordis Corporation.

Dr. Alexander is a consultant to Schering-Plough and receives research funding from Merck, Schering-Plough, and BMS.

References

  1. 1.
    Rao SV, Jollis JG, Harrington RA et al (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292:1555–1562PubMedCrossRefGoogle Scholar
  2. 2.
    Rao SV, O’Grady K, Pieper KS et al (2005) Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96:1200–1206PubMedCrossRefGoogle Scholar
  3. 3.
    Eikelboom JW, Mehta SR, Anand SS, Xie C et al (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774–782PubMedCrossRefGoogle Scholar
  4. 4.
    Sabatine MS, Cannon CP, Gibson CM et al, for the CLARITY–TIMI 28 Investigators (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189Google Scholar
  5. 5.
    Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464–1476Google Scholar
  6. 6.
    Antman EM, Morrow DA, McCabe CH et al, for the ExTRACT-TIMI 25 Investigators (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354:1477–1488Google Scholar
  7. 7.
    Montalescot G, White HD, Gallo R et al, for the STEEPLE Investigators (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. New Engl J Med 355:1006–1017Google Scholar
  8. 8.
    Stone GW, McLaurin BT, Cox, DA et al, for the ACUITY Investigators (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203–2216Google Scholar
  9. 9.
    Moscucci M, Fox KAA, Cannon CP et al, for the GRACE Investigators (2003) Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24:1815–1823Google Scholar
  10. 10.
    Farouque HM, Tremmel JA, Raissi Shabari F et al (2005) Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices. J Am Coll Cardiol 45:363–368PubMedCrossRefGoogle Scholar
  11. 11.
    Yang X, Alexander KP, Chen AY et al, for the CRUSADE Investigators (2005) Blood transfusion and non-ST-segment elevation acute coronary syndromes: results from CRUSADE. J Am Coll Cardiol 46:1479–1487Google Scholar
  12. 12.
    Manoukian SR, Feit F, Mehran R et al (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes, An analysis from the ACUITY Trial. J Am Coll Cardiol 49:1362–1368PubMedCrossRefGoogle Scholar
  13. 13.
    Alexander KP, Chen AY, Roe MT et al, for the CRUSADE Investigators (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108–3116Google Scholar
  14. 14.
    Alexander KP, Chen AY, Newby LK et al, for the CRUSADE Investigators (2006) Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 114:1380–1387Google Scholar
  15. 15.
    GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682CrossRefGoogle Scholar
  16. 16.
    Lincoff AM, Bittl JA, Harrington RA et al, for the REPLACE-2 Investigators (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853–863Google Scholar
  17. 17.
    Chesebro JH, Knatterud G, Roberts R et al (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:142–154PubMedGoogle Scholar
  18. 18.
    Ferguson JJ, Califf RM, Antman EM et al, for the SYNERGY Trial Investigators (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292:45–54Google Scholar
  19. 19.
    Cohen M, Demers C, Gurfinkel EP et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337:447–452PubMedCrossRefGoogle Scholar
  20. 20.
    Peterson ED, Coombs LP, DeLong ER, Haan CK, Ferguson TB (2004) Procedural volume as a marker of quality for CABG surgery. JAMA 291:195–201PubMedCrossRefGoogle Scholar
  21. 21.
    The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339:436–443Google Scholar
  22. 22.
    Boersma E, Harrington RA, Moliterno DJ et al (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359:189–198PubMedCrossRefGoogle Scholar
  23. 23.
    Peters RJG, Mehta SR, Fox KAA et al, for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators (2003) Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108:1682–1687Google Scholar
  24. 24.
    Bovill EG, Terrin ML, Stump DC et al (1991) Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 115:256–265PubMedGoogle Scholar
  25. 25.
    Rao SV, O’Grady K, Pieper KS et al (2006) A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47:809–816PubMedCrossRefGoogle Scholar
  26. 26.
    Majure DT, Aberegg SK (2006) Fondaparinux versus enoxaparin in acute coronary syndromes. N Engl J Med 354:2829; author reply 2830Google Scholar
  27. 27.
    Fox KAA, Bassand JP, Wallentin L et al (2006) The Efficacy and Safety of Fondaparinux Versus Enoxaparin in Non-ST Elevation Acute Coronary Syndrome: Impact of Renal Dysfunction (OASIS 5). ACC 2006, presentation #972-222, presented 13 Mar 2006Google Scholar
  28. 28.
    Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction— executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 50:652–726CrossRefGoogle Scholar
  29. 29.
    Kaul S, Shak PK, Diamond GA (2006) Bivalirudin during early invasive strategy for acute coronary syndromes: noninferiority in ACUITY lies in the eyes of the beholder. Circulation 114:II-552: (abstr 2652)Google Scholar
  30. 30.
    Kirtane AJ, Piazza G, Murphy SA et al, for the TIMI Study Group (2006) Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 47:2374–2379Google Scholar
  31. 31.
    EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956–961Google Scholar
  32. 32.
    Smith SC Jr., Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363–2372PubMedCrossRefGoogle Scholar
  33. 33.
    EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87–92CrossRefGoogle Scholar
  34. 34.
    ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356:2037–2044CrossRefGoogle Scholar
  35. 35.
    Bhatt DL, Fox KA, Hacke W, et al, for the CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706–1717Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Marc Cohen
    • 1
    Email author
  • Karen P. Alexander
    • 2
  • Sunil V. Rao
    • 2
  1. 1.The Division of CardiologyNewark Beth Israel Medical CenterNewarkUSA
  2. 2.The Division of CardiologyDuke University Medical CenterDurhamUSA

Personalised recommendations